• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

byThomas SuandHarsh Shah
March 18, 2021
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Base-case analysis for weekly testing availability predicted large reductions in infections, hospitalizations, and mortality.

2. The cost per death averted varied dramatically according to behavioral responses but remained well below the range of commonly accepted values of a statistical life.

Evidence Rating Level: 2 (Good)

Study Rundown: A number of strategies have been verified and adopted as cornerstones for containing the coronavirus disease 2019 (COVID-19) pandemic. High-frequency, home-based antigen testing, however, has generated significant controversy. While the speed and accessibility of this tool are advantages, critics cite the relatively low specificity and sensitivity of this type of testing as major drawbacks. This study utilized a simple compartmental epidemic model of the United States over 60 days to quantify these contentions. The study determined the testing intervention would be effective and cost-effective in preventing infections, hospitalizations, and deaths. The model was also robust, predicting the cost per death averted would remain below the minimum benchmark value of a statistical life. The study was limited by the model-based evaluation and the benefits posed in densely populated locations such as schools and concerts. Nonetheless, these findings are significant, as they suggest the implementation of a mass testing program would likely be highly worthwhile in the general population.

Click here to read the study in Annals of Internal Medicine

Relevant Reading: Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?

In-Depth [prospective cohort]: This study involved a 60-day projection of the United States population with variable parameters corresponding to hypothetical test performance (and behavioral responses. Input data were informed by the Centers for Disease Control and Prevention guidance and existing literature. The study assessed health outcomes and economic performance. In the base case analysis, weekly home testing reduced infections from 11.6 million to 8.8 million and deaths from 119,000 to 103,000. Inpatient costs were slightly reduced from $6.5 billion to $5.9 billion, but losses in productivity increased from $3.5 billion (19.6 million days) to $14 billion (78 million days). Test kits were projected to cost an additional $12.5 billion. Despite this overall monetary increase, the cost per infection averted was $7890, and the cost per death averted was $1.43 million, a value well below the most stringent recommended benchmark of $5.3 million per statistical life (central estimate, $11.3 million; upper bound, $17.2 million). In the worst-case behavioral scenario (25% participation; 25% isolation of persons with positive results; 33% rate of daily abandonment), the cost per death averted increased to $4.1 million, but the number of infections was still reduced by over 600,000. Overall, the use of weekly testing reduced infections, hospitalizations, and mortality.

RELATED REPORTS

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: coronarvirusRapid antigen-based home testingSARS-CoV-2
Previous Post

Short-course antimicrobial therapy effective for pediatric community-acquired pneumonia

Next Post

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Next Post
#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.